Actovegin Research Overview

Background and Composition

Actovegin (manufactured by Takeda Austria GmbH, formerly Nycomed) is produced by ultrafiltration of calf blood to remove all components above 5 kDa, retaining a complex mixture of low-molecular-weight biologically active substances. The resulting haemodialysate is standardised by biological activity assay rather than chemical composition — making Actovegin, like Cerebrolysin, a biologically complex extract defined by its production process and functional activity rather than a single molecular entity.

The identified components of Actovegin include: amino acids and their derivatives, oligopeptides (below 5 kDa), nucleosides (inosine, hypoxanthine), monosaccharides (deoxyribose, inositol phosphate-oligosaccharides), electrolytes, and trace elements. The inositol phosphate-oligosaccharides fraction has attracted particular research attention as the likely mediator of Actovegin's insulin-like effects on cellular glucose uptake — they appear to function as inositolglycan second messengers that mimic insulin's post-receptor signalling for GLUT-1 and GLUT-4 translocation.

• Source Material: Deproteinised haemodialysate of calf blood
• MW Cutoff: <5 kDa (all larger molecules removed)
• Key Bioactive Fractions: Inositol phosphate-oligosaccharides; nucleosides; oligopeptides
• Primary Mechanism: GLUT-1 upregulation; oxidative phosphorylation support; anti-apoptotic
• Regulatory Status: Approved in Russia, Germany, Austria, China, Japan; research use elsewhere
• Administration: IV infusion; IM injection; oral tablets; topical cream/gel

Mechanisms of Action

GLUT-1 Upregulation & Insulin-Like Effect

Inositol phosphate-oligosaccharides mimic insulin second messenger signalling, upregulating GLUT-1 glucose transporter expression and facilitating cellular glucose uptake in insulin-resistant states. This effect operates in neurons, endothelial cells, and peripheral nerve Schwann cells — tissues with high metabolic demands vulnerable to glucose deprivation.

Oxidative Phosphorylation Enhancement

Actovegin components support mitochondrial function by increasing substrate availability (pyruvate, nucleotides) and reducing electron leak from the electron transport chain. Measured increases in cellular ATP content and oxygen utilisation efficiency have been documented in hypoxic cell models after Actovegin treatment.

Anti-Apoptotic Signalling

Reduces cytochrome c release and caspase-3 activation in neurons and endothelial cells under ischaemic and hyperglycaemic stress. AKT and ERK survival pathway activation proposed as the downstream mechanism. Neuronal apoptosis reduction has been most consistently documented in preclinical models.

Antioxidant Activity

Reduces ROS generation in hypoxic and ischaemic tissue. Restores SOD activity. Reduces lipid peroxidation. Inosine and hypoxanthine components contribute direct free radical scavenging capacity alongside enzyme-mediated antioxidant effects.

Diabetic Polyneuropathy Research

Actovegin's most rigorously studied clinical application is diabetic polyneuropathy (DPN) — a progressive nerve damage condition affecting up to 50% of diabetic patients, driven by hyperglycaemia-induced oxidative stress, impaired glucose utilisation in peripheral nerve tissue, and microvascular insufficiency. The ACTINOS trial — a multicentre, randomised, double-blind, placebo-controlled Phase IV trial enrolling 567 T2DM patients with DPN — demonstrated that IV Actovegin (2,000 mg/day for 20 days) followed by oral Actovegin (1,800 mg/day for 160 days) produced significant improvements in neuropathic symptom score (NSS), neuropathy disability score (NDS), and nerve conduction velocity compared to placebo at 6 months.

The mechanistic rationale for Actovegin in DPN is directly linked to its insulin-mimetic glucose uptake effects: peripheral nerve Schwann cells and neurons rely heavily on GLUT-1-mediated glucose transport, which is impaired in the hyperglycaemic, insulin-resistant environment of T2DM. By facilitating GLUT-1-mediated glucose uptake independently of insulin signalling, Actovegin restores energy availability in energy-deprived nerve tissue — addressing the metabolic deficit underlying DPN.

Stroke and Ischaemic Brain Injury Research

Actovegin has been studied in acute ischaemic stroke and post-stroke recovery across multiple clinical trials in Russia, Germany, and China. The ARTEMIDA trial — a multicentre Phase IV RCT enrolling 503 patients with acute ischaemic stroke — evaluated IV Actovegin (2,000 mg/day for 10 days) followed by oral continuation for 6 months. The primary endpoint (cognitive outcomes at 6 months, measured by MMSE and ADAS-cog) showed significant benefit in the Actovegin group compared to placebo, with the largest benefit observed in patients with post-stroke cognitive impairment (PSCI) — a common and debilitating stroke sequela.

Preclinical data supporting these findings includes consistent demonstration of reduced infarct volume, attenuated neuronal apoptosis, and improved motor and cognitive recovery metrics across multiple rodent stroke models. The proposed mechanism involves both Actovegin's anti-apoptotic protection of neurons in the ischaemic penumbra and its metabolic support of energy-deprived peri-infarct tissue through GLUT-1 upregulation and mitochondrial efficiency enhancement.

• Indication: Diabetic Polyneuropathy — Key Trial: ACTINOS (n=567, RCT) — Primary Finding: Significant NSS, NDS improvement; nerve conduction improvement vs placebo — Evidence Quality: High — Phase IV multicentre RCT
• Indication: Post-Stroke Cognitive Impairment — Key Trial: ARTEMIDA (n=503, RCT) — Primary Finding: Significant cognitive improvement at 6 months in PSCI patients — Evidence Quality: High — Phase IV multicentre RCT
• Indication: Peripheral Vascular Disease — Key Trial: Multiple RCTs — Primary Finding: Improved walking distance; reduced ischaemic pain — Evidence Quality: Moderate — heterogeneous trial designs
• Indication: Wound Healing (diabetic) — Key Trial: Multiple RCTs (topical + systemic) — Primary Finding: Accelerated wound closure; reduced infection rates — Evidence Quality: Moderate
• Indication: TBI Recovery — Key Trial: Multiple small RCTs — Primary Finding: Improved neurological recovery scores — Evidence Quality: Low-Moderate — small samples

WADA and Sport Research Context > > Actovegin achieved international notoriety when it was found in medical waste at the 2000 Tour de France, raising questions about its use as a potential performance-enhancing agent through its oxygen utilisation and cellular energy effects. Actovegin was subsequently investigated by WADA but was not added to the prohibited list, as no evidence of performance enhancement in healthy athletes was substantiated. This history is relevant to understanding the research interest in Actovegin's metabolic effects in non-pathological contexts, though its clinical utility is specifically established in disease states characterised by impaired cellular energy metabolism.

Research Use Only. Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Actovegin is an approved pharmaceutical in Russia, Germany, Austria, China, Japan, and other jurisdictions; it is not FDA-approved in the United States. This content does not constitute medical advice. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Ziegler D, et al. "Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis." *Diabet Med*. 2004;21(2):114–121.

1. Saletu B, et al. "EEG brain mapping and psychometric studies with deproteinized haemodialysate of calf blood (Actovegin) in elderly patients with organic brain syndrome." *Neuropsychobiology*. 1990–1991;24(3):135–148.

1. Guekht A, et al. "ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Dose-finding Actovegin): a randomized controlled trial to assess the efficacy of Actovegin in poststroke cognitive impairment." *Stroke*. 2017;48(5):1262–1270.

1. Ziegler D, et al. "Actovegin in the treatment of patients with diabetic polyneuropathy." *Diabetes Metab Res Rev*. 2009;25(6):542–549.

1. Fedorovich SV, et al. "Actovegin affects ATP production and mitochondrial membrane potential in rat brain synaptosomes." *Biochemistry (Moscow) Suppl*. 2010;4(3):262–269.